Previous close | 210.55 |
Open | N/A |
Bid | 216.10 |
Ask | 222.70 |
Strike | 770.00 |
Expiry date | 2025-12-19 |
Day's range | 210.55 - 210.55 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Insightful Analysis of Regeneron's Financials and Strategic Positioning
Regeneron stock jumped early Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea.
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.